# Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Study · id `cardio:ct-nct03904693` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03904693](<https://clinicaltrials.gov/study/NCT03904693>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03904693

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 187 participants.

## Technical summary

Registry record NCT03904693. Randomized; quadruple masking; primary purpose treatment. Start 2019-07-29 (actual); primary completion 2022-08-23 (actual). Results posted on 2023-11-13.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 187 participants (enrolled count; ClinicalTrials.gov record NCT03904693, source copy `cardio:ctgov-nct03904693-2025-12-19`, retrieved 2026-10-31)
- Started: 2019-07-29 (actual) (ClinicalTrials.gov record NCT03904693, source copy `cardio:ctgov-nct03904693-2025-12-19`, retrieved 2026-10-31)
- Primary completion: 2022-08-23 (actual) (ClinicalTrials.gov record NCT03904693, source copy `cardio:ctgov-nct03904693-2025-12-19`, retrieved 2026-10-31)
- Completion: 2024-09-27 (actual) (ClinicalTrials.gov record NCT03904693, source copy `cardio:ctgov-nct03904693-2025-12-19`, retrieved 2026-10-31)
- Results first posted: 2023-11-13 (ClinicalTrials.gov record NCT03904693, source copy `cardio:ctgov-nct03904693-2025-12-19`, retrieved 2026-10-31)
- Countries: United States; Australia; Brazil; Bulgaria; Canada; China; Czechia; Germany; Hungary; Italy; Japan; Malaysia; Mexico; Poland; Russia; South Africa; Spain; Taiwan; Türkiye (ClinicalTrials.gov record NCT03904693, source copy `cardio:ctgov-nct03904693-2025-12-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03904693-2025-12-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
- Acronym: A DUE
- Condition: Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Intervention (Drug): FDC macitentan/tadalafil
- Intervention (Drug): Macitentan 10 mg
- Intervention (Drug): Tadalafil 40 mg
- Intervention (Drug): Placebo FDC
- Intervention (Drug): Placebo macitentan
- Intervention (Drug): Placebo tadalafil
- Lead sponsor: Actelion
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Actelion (`cardio:org-actelion`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension (`cardio:pubmed-38267108`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Long-Term Treatment with Single-Tablet Combination of Macitentan and Tadalafil in Pulmonary Arterial Hypertension: Results from A DUE and Its Open-Label Period (`cardio:pubmed-41820779`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 118067d9e20cceb96c3993725e1dfac08bdb55292844f3d01ac572d5c580a423
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
